Guidance on HPV vaccination in EU countries: focus on boys, people living with HIV and 9-valent HPV vaccine introduction
This document summarises evidence from studies included in the licensing file of HPV vaccines together with postlicensure, peer-reviewed data and analysis where available. This guidance does not address the safety of HPV vaccines observed during the pre- and post-licensing period.
Expert opinion on the Introduction of HPV Vaccines in EU Countries
This guidance report lays down the scientific basis for the potential introduction of human papillomavirus (HPV) vaccines in order to help EU Member States to make policy choices
Evidence of safety of HPV vaccines in people living with HIV
What is the evidence on the safety of the HPV vaccine in HIV-infected men and women?
Evidence of safety of HPV vaccines in males
What is the evidence on the safety of the HPV vaccines in males?
Technical guidance on the Introduction of HPV vaccines in European Union countries – an update
In January 2008, a panel of ECDC experts produced the Guidance for the introduction of HPV vaccines in EU countries. Since then, the European Union has come a long way: most countries have implemented national vaccination programmes for adolescent girls and a significant number have also introduced catch-up programmes for young women.
Evidence of efficacy of HPV vaccines in males
What is the evidence on the efficacy of the HPV vaccines in males?
Evidence of immunogenicity of HPV vaccines in people living with HIV
What is the evidence on the immunogenicity of the HPV vaccine in HIV-infected men and women?